Circulating-free DNA: A promising tool for early detection of myocardial infarction.

Int J Cardiol Cardiovasc Risk Prev

Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Bertam, Penang, 13200, Malaysia.

Published: December 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Myocardial infarction (MI) is a leading global cause of mortality, necessitating novel biomarkers for early diagnosis and prognosis. This review explores circulating cell-free DNA (cfDNA) as a minimally invasive tool for MI detection, focusing on its mechanistic role, diagnostic accuracy, and potential in personalized medicine. CfDNA levels rise rapidly post-ischemic event, correlating with myocardial damage and complementing troponins. Liquid biopsies using cfDNA enable dynamic monitoring of disease progression, but methodological variability and low concentrations limit its standalone use. Standardizing protocols and integrating cfDNA into multi-marker panels could enhance its clinical utility, positioning it as a transformative cardiovascular diagnostic tool.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357262PMC
http://dx.doi.org/10.1016/j.ijcrp.2025.200484DOI Listing

Publication Analysis

Top Keywords

myocardial infarction
8
circulating-free dna
4
dna promising
4
promising tool
4
tool early
4
early detection
4
detection myocardial
4
infarction myocardial
4
infarction leading
4
leading global
4

Similar Publications

Introduction: 5-Hydroxymethyl furfural (5-HMF) is a furan compound with a molecular formula of CHO. Studies have found that 5-HMF has many pharmacological effects, such as improving hemorheology, anti-inflammatory, antioxidant activity and anti-myocardial ischemia. Identifying the preventive effect of 5-HMF against ischemic stroke and its possible mechanism was the aim of this investigation.

View Article and Find Full Text PDF

The Systemic Immune-Inflammation Index Predicts Long-Term Outcomes in Patients With Unstable Angina and Diabetes After Revascularization.

Rev Cardiovasc Med

August 2025

Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, 100029 Beijing, China.

Background: The incidence of unstable angina (UA), a type of cardiovascular disease (CVD), has increased in recent years. Meanwhile, timely percutaneous coronary intervention (PCI) or percutaneous transluminal coronary angioplasty (PTCA) procedures are crucial for patients with UA who also have diabetes mellitus (DM). Additionally, exploring other factors that may influence the prognosis of these patients could provide long-term benefits.

View Article and Find Full Text PDF

Coronary microvascular disease has been found to increase the incidence of the composite endpoint for cardiovascular events and affect coronary revascularization. Coronary microvascular disease is often accompanied by epicardial disease, and despite successful revascularization and optimal medications, coronary microvascular disease may lead to reduced exercise tolerance and worsening clinical symptoms. Moreover, despite advances in percutaneous coronary intervention for coronary revascularization, the management of microvascular obstruction in reperfused myocardial tissue remains challenging and is a high-risk procedure.

View Article and Find Full Text PDF

Background: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score represents a meaningful predictor in many cardiovascular diseases. However, the predictive utility of this score for the outcome of patients admitted to the intensive care unit (ICU) due to acute myocardial infarction (AMI) has yet to be fully elucidated.

Methods: Information from the Medical Information Mart for Intensive Care (MIMIC)-IV v3.

View Article and Find Full Text PDF

Background: Globally, acute myocardial infarction (AMI) is among the primary causes of mortality. The ideal approach for blood pressure (BP) management for patients experiencing ST-segment elevation myocardial infarction (STEMI) who receive percutaneous coronary intervention (PCI) remains a topic of ongoing debate. Current guidelines on BP management lack specific recommendations for STEMI patients undergoing PCI, resulting in substantial individual variability and uncertainties in clinical treatment strategies.

View Article and Find Full Text PDF